Advertisement

Drugs

pp 1–12 | Cite as

Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice

  • Kayla M. MillerEmail author
  • Michael J. Brenner
Review Article
  • 33 Downloads

Abstract

Acutely ill hospitalized medical patients remain at high thromboembolic risk for several weeks after discharge. Previous trials with extended-duration thromboprophylaxis using enoxaparin, apixaban, and rivaroxaban failed to achieve acceptable net clinical benefit, largely due to excess of major bleeding. Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio. The phase III APEX trial (N = 7513) compared a betrixaban 160 mg loading dose followed by 80 mg once daily for 35–42 days, with enoxaparin 40 mg once daily for 6–14 days; the betrixaban dose was reduced for renal impairment or a concomitant strong P-glycoprotein (P-gp) inhibitor. The primary efficacy endpoint of composite thrombotic events was not different between treatment arms in cohort 1 (d-dimer ≥ 2 × upper limit of normal). Subsequent exploratory analyses showed a statistically significant difference favoring betrixaban for symptomatic venous thromboembolism and net clinical benefit in the overall population. For the primary safety outcome, betrixaban did not significantly increase major bleeding compared with enoxaparin. Based on available data from the APEX trial and subanalyses, the use of betrixaban in patients similar to those enrolled in the APEX trial can reduce the risk of thromboembolic events without increasing the risk of major bleeding. Patients who may benefit more from betrixaban therapy include those with elevated d-dimer, history of venous thromboembolism, hospitalized for ischemic stroke, hospitalized for heart failure with N-terminal pro-B-type natriuretic peptide ≥ 1975 ng/L, or two or more VTE risk factors. Reduced-dose betrixaban does not appear to provide the same clinical utility as full-dose betrixaban.

Notes

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this manuscript.

Conflict of Interest

Dr Miller declares no conflicts of interest. Dr Brenner declares no conflicts of interest.

References

  1. 1.
    Beckman MG, Hooper C, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495–501.CrossRefGoogle Scholar
  2. 2.
    Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94:750–9.PubMedGoogle Scholar
  3. 3.
    Cohen AT, Spiro TE, Spyropoulos AC, et al. d-Dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 2014;12:479–87.CrossRefGoogle Scholar
  4. 4.
    Spyropoulos AC, Anderson FA, Fitzgerald G, et al. Predictive and associative models to identify hospitalised medical patients at risk for VTE. Chest. 2011;140:706–14.CrossRefGoogle Scholar
  5. 5.
    Mahan CE, Fisher MD, Mills RM, et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res. 2013;132:520–6.CrossRefGoogle Scholar
  6. 6.
    Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S–226S.CrossRefGoogle Scholar
  7. 7.
    Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793–800.CrossRefGoogle Scholar
  8. 8.
    Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325–9.CrossRefGoogle Scholar
  9. 9.
    Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–9.CrossRefGoogle Scholar
  10. 10.
    Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8–18.CrossRefGoogle Scholar
  11. 11.
    Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–23.CrossRefGoogle Scholar
  12. 12.
    Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–77.CrossRefGoogle Scholar
  13. 13.
    Spyraopoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018.  https://doi.org/10.1056/NEJMoa1805090.CrossRefGoogle Scholar
  14. 14.
    Mahan CE, Liu Y, Turpie G, et al. External validation of a risk assessment model for venous thromboembolism in the hospitalized acutely-ill medical patient (VTE-VALOURR). Thromb Haemost. 2014;112:692–9.CrossRefGoogle Scholar
  15. 15.
    Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the international medical prevention registry on venous thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3:e001152.  https://doi.org/10.1161/JAHA.114.001152.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534–44.  https://doi.org/10.1056/nejmoa1601747.CrossRefPubMedGoogle Scholar
  17. 17.
    Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–51.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Huisman MV, Klok FA. Pharmacological properties of betrixaban. Eur Heart J Suppl. 2018;20(Suppl E):E1–2.Google Scholar
  19. 19.
    Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J. 2014;167(3):335–41.  https://doi.org/10.1016/j.ahj.2013.11.006.CrossRefPubMedGoogle Scholar
  20. 20.
    Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Gibson CM, Hernandez AF, Gold A. Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J. 2015;169(1):186–7.  https://doi.org/10.1016/j.ahj.2014.09.004.CrossRefPubMedGoogle Scholar
  21. 21.
    Chi G, Goldhaber SZ, Hull RD, Hernandez AF, Kerneis M, Al Khalfan F, Cohen AT, Harrington RA, Gibson CM. Thrombus burden of deep vein thrombosis and its association with thromboprophylaxis and d-dimer measurement: insights from the APEX trial. Thromb Haemost. 2017;117(12):2389–95.  https://doi.org/10.1160/TH17-08-0538.CrossRefPubMedGoogle Scholar
  22. 22.
    Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. J Thromb Thrombolysis. 2018;45(1):1–8.  https://doi.org/10.1007/s11239-017-1583-0.CrossRefPubMedGoogle Scholar
  23. 23.
    Chi G, Januzzi JL, Korjian S, Daaboul Y, Goldhaber SZ, Hernandez AF, Hull RD, Gold A, Cohen AT, Harrington RA, Gibson CM. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017;44(4):457–65.  https://doi.org/10.1007/s11239-017-1552-7.CrossRefPubMedGoogle Scholar
  24. 24.
    Gibson CM, Nafee T, Yee MK, Chi G, Korjian S, Daaboul Y, AlKhalfan F, Kerneis M, Goldhaber SZ, Hull R, Hernandez AF, Cohen AT, Harrington RA. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018;198:84–90.  https://doi.org/10.1016/j.ahj.2017.12.015.CrossRefPubMedGoogle Scholar
  25. 25.
    Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients: findings from the APEX trial (acute medically ill venous thromboembolism prevention with extended duration betrixaban trial). Circulation. 2018;137(1):91–4.  https://doi.org/10.1161/CIRCULATIONAHA.117.031187.CrossRefPubMedGoogle Scholar
  26. 26.
    Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, APEX Investigators. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban). Circulation. 2017;135(7):648–55.  https://doi.org/10.1161/circulationaha.116.025427.CrossRefPubMedGoogle Scholar
  27. 27.
    Arbetter DF, Jain P, Yee MK, Michalak N, Hernandez AF, Hull RD, Goldhaber SZ, Harrington RA, Gold A, Cohen AT, Gibson CM. Competing risk analysis in a large cardiovascular clinical trial: an APEX substudy. Pharm Stat. 2017;16(6):445–50.  https://doi.org/10.1002/pst.1823.CrossRefPubMedGoogle Scholar
  28. 28.
    Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT, APEX Investigators. The safety and efficacy of full- versus reduced-dose betrixaban in the acute medically ill VTE (venous thromboembolism) prevention with extended-duration betrixaban (APEX) trial. Am Heart J. 2017;185:93–100.  https://doi.org/10.1016/j.ahj.2016.12.004.CrossRefPubMedGoogle Scholar
  29. 29.
    Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA, APEX Investigators. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy. J Am Heart Assoc. 2017;6(7):e006015.  https://doi.org/10.1161/jaha.117.006015.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017;15(10):1913–22.  https://doi.org/10.1111/jth.13783.CrossRefPubMedGoogle Scholar
  31. 31.
    Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation. 2012; 125:1605–16.CrossRefGoogle Scholar
  32. 32.
    Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.CrossRefGoogle Scholar
  33. 33.
    Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol. 2007;50:205–14.CrossRefGoogle Scholar
  34. 34.
    Mishra RK, Beatty AL, Jaganath R, et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the heart and soul study. J Am Heart Assoc. 2014;3:e000907.  https://doi.org/10.1161/JAHA.114.000907.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.CrossRefGoogle Scholar
  36. 36.
    Turpie AGG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101:68–76.CrossRefGoogle Scholar
  37. 37.
    Connolly SJ, Eieklboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013;34:1498–505.CrossRefGoogle Scholar
  38. 38.
    Bevyxxa® [package insert]. South San Francisco: Portola Pharmaceuticals, Inc; 2017.Google Scholar
  39. 39.
    Center for Drug Evaluation and Research. Approved drugs—FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. 23 June 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm. Accessed 2 Sept 2018.
  40. 40.
    Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017;103:623–8.CrossRefGoogle Scholar
  41. 41.
    Righini M, Goehring C, Bounameaux H, et al. Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med. 2000;109:357–61.CrossRefGoogle Scholar
  42. 42.
    Righini M, Van Es J, Den Exter PL, et al. Age-adjusted d-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117–24.CrossRefGoogle Scholar
  43. 43.
    Xarelto® [package insert]. Titusville: Janssen Pharmaceutical Inc; 2011.Google Scholar

Copyright information

© This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2019

Authors and Affiliations

  1. 1.VA Ann Arbor Healthcare SystemAnn ArborUSA

Personalised recommendations